Vivace Therapeutics
Vivace Therapeutics, Inc.
Vivace Therapeutics, Inc. is a pioneering biotechnology firm focused on creating innovative cancer treatments that specifically target the Hippo-YAP signaling pathway. The company aims to deliver solutions for cancer patients with limited options, particularly those suffering from challenging malignancies driven by pathway dysregulation.
Products & Team
VT3989
VT3989 is an innovative small molecule drug designed to inhibit TEAD autopalmitoylation within the Hippo signaling pathway. This mechanism aims to counteract the effects of pathway dysregulation that can lead to tumorigenesis, particularly in cancers like mesothelioma and other solid tumors characterized by NF2 mutations.
VT3989 addresses a significant unmet need in oncology by offering potential therapeutic benefits to patients suffering from advanced mesothelioma and other solid tumors that are resistant to existing treatment options.
Patients facing limited treatment alternatives for aggressive cancers and those who have not responded effectively to available therapies are the core focus. The need for innovative solutions is acute among these demographics.